Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Inflated prices to...

    Inflated prices to 1000 per cent; Lupin, Sun Pharma, Dr Reddys, others face lawsuit

    Farhat NasimWritten by Farhat Nasim Published On 2019-05-14T16:57:02+05:30  |  Updated On 13 Aug 2021 9:09 AM GMT

    Mumbai: In a major setback, a group of domestic pharmaceutical companies including Zydus Cadila, Lupin, Aurobindo Pharma, Dr Reddy's Labs, Wockhardt, Glenmark, Sun Pharma are in a soup as 40 US states have filed legal proceedings against these pharma majors.


    According to a recent report by TOI, lawsuits have been filed against pharma majors for allegedly conspiring in inflating prices of widely prescribed generic medicines as high as 1000 per cent.


    Besides domestic firms, global pharma biggies including Teva, Pfizer, Sandoz and Mylan are also under alleged implication.


    It has been reported that the complaint lodged by 44 US states in US district court in Connecticut mentions that 20 drug companies allegedly engaged in conspiracies to split the drug market in order to evade competition and also prevent prices from falling or rising.


    Expressing concern over the same, experts state that the domestic industry, already struggling with pricing pressure in the US, faces one of the biggest such probes ever which, if proven, can suffer prosecution and financial burden on companies.


    The development put a restriction on the entire pharma sector as the US is the most profitable market, contributing a significant portion to revenues.


    Presently, the case as lengthy as 500 pages was filed by the US states on May 10. The lawsuit expands a complaint of price collusion filed in the year 2016, which is still pending in the US courts. The case was first investigated in 2014.


    The hike in drug prices from both branded as well as generic manufacturers has sparked resentment, with criticism coming from across the political spectrum, including from President Donald Trump.


    Over time, the industry-wide scheme reportedly impacted prices of over 300 generic drugs in the US including HIV, diabetes, asthma medication, high cholesterol, oral antibiotics, blood thinners, cancer drugs, contraceptives and antidepressants, reports TOI.


    Commenting on the same, Surajit Pal associate vice-president, Prabhudas Lilladher told TOI, "The role of domestic companies (under investigation) appears to be minimal, probably to the extent of three to four molecules, while we expect the penalty would not be over $50 million each."

    https://pubads.g.doubleclick.net/gampad/ads?iu=/21687779244/clinicalkey_video_ad&description_url=[placeholder]&tfcd=0&npa=0&sz=640x480&gdfp_req=1&output=vast&unviewed_position_start=1&env=vp&impl=s&correlator=

    Meanwhile, stock prices of most companies witnessed a sharp drop on the Bombay Stock Exchange to the tune of 4-9% recently as the US probe on price-fixing seems to have impacted the overall domestic pharma sector. Consequently, Sun Pharma scrip tanked the most by nearly 10% to Rs 397.


    However, domestic companies are of the opinion that they would defend these allegations. A Sun Pharma spokesperson told TOI, "We believe the allegations made in these lawsuits are without merit, and we will continue to vigorously defend against them."


    Also Read: Setback to Sun Pharma: NPPA refuses to give relief of price cap exemption for Gemcitabine

    antidepressants asthma medication Aurobindo Pharma blood thinners cancer drugs contraceptives diabetes Dr Reddy's generic drugs Glenmark high cholesterol HIV India Pharma companies inflating price inflation Lupin Mylan oral antibiotics Pfizer pharma co conspiracy Pharma companies Pharma companies India Pharma companies news prescription medicines Sandoz Sun Pharma Taro Teva Wockhardt zydus 
    Source : with inputs

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier

      This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:

      Search only trustworthy HONcode health websites:

      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2020 Minerva Medical Treatment Pvt Ltd

      © 2020 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      X